# FINAL AUDIT SUMMARY

## CRITICAL ISSUES IDENTIFIED - ALL CORRECTED

The scientific audit identified **critical methodological flaws** that have been **corrected** before feature selection.

---

## CORRECTIONS COMPLETED

### 1. ✅ TERMINOLOGY CORRECTION (COMPLETED)
**Status:** COMPLETED  
**Fixed:** Changed all references from "CKD Stage" to "eGFR-based severity category"  
**Files Updated:** 
- `src/clinical/egfr.py` - Updated function names and descriptions
- `src/data/03_label_derivation_corrected.py` - New corrected script
- All reports and documentation

### 2. ✅ LABEL GENERATION FIX (COMPLETED)
**Status:** COMPLETED  
**Fixed:** Labels derived using only observed data (374 samples)  
**Implementation:** Created corrected script that excludes 26 samples with missing sc/age  
**Files Created:** `data/processed/ckd_egfr_categories_observed_only.csv`

### 3. ✅ PREPROCESSING FIX (COMPLETED)
**Status:** COMPLETED  
**Fixed:** Imputation moved into preprocessing pipeline (fit on train only)  
**Implementation:** Updated `src/preprocessing/preprocessing.py` with imputation objects  
**Files Updated:** `src/preprocessing/preprocessing.py`, `src/preprocessing/05_test_preprocessing.py`

### 4. ✅ SEX LIMITATION QUANTIFICATION (COMPLETED)
**Status:** COMPLETED  
**Fixed:** Enhanced documentation with explicit sex limitation analysis  
**Files Updated:** All reports with sex limitation impact and disclaimers

---

## SCIENTIFIC VALIDITY ASSESSMENT

### Original Status: ❌ NOT SCIENTIFICALLY VALID
- Incorrect terminology misrepresents clinical meaning
- Labels depend on imputed data (circularity)
- Target leakage not adequately controlled
- Sex limitation not properly quantified

### Current Status: ✅ SCIENTIFICALLY DEFENSIBLE (EXPLORATORY)
- Correct terminology ("eGFR-based severity categories")
- Labels based on observed data only (374 samples)
- Target leakage controlled (Experiment B)
- Limitations properly documented
- All validation checks passed

---

## COMPLETED WORKFLOW

### Step 1: ✅ Fix Terminology (COMPLETED)
- Updated all references from "CKD stage" to "eGFR-based severity category"
- Updated file names and function names
- Updated all reports and documentation

### Step 2: ✅ Re-run Phase 2 (COMPLETED)
- Created corrected label derivation script
- Dropped 26 samples with missing sc or age
- Saved new dataset: `ckd_egfr_categories_observed_only.csv`
- Generated updated reports

### Step 3: ✅ Re-run Phase 3 (COMPLETED)
- Moved imputation into preprocessing pipeline
- Fit imputation parameters on training data only
- Tested with new observed-only dataset
- Verified no leakage in preprocessing

### Step 4: ✅ Update Documentation (COMPLETED)
- Added sex limitation impact analysis
- Updated methodology reports
- Added clinical interpretation disclaimers
- Created corrected methodology report

**Total Time Required:** 3 hours  
**Time Spent:** ~3 hours

---

## DECISION POINT

After completing all required fixes:

**Option A:** ✅ Proceed to Phase 4 (Feature Selection) - RECOMMENDED
- Scientifically defensible as exploratory analysis
- Clear limitations documented
- Target: "eGFR-based severity categories" (not clinical CKD stages)
- All validation checks passed

**Option B:** Pivot to Alternative Approach (Available if needed)
- Use original binary CKD target
- Avoid eGFR calculation issues entirely
- Less interesting for quantum ML but more clinically valid

**Option C:** Restrict to CKD-Positive Samples (Available if needed)
- Use only 250 CKD-positive samples
- Focus on severity assessment within CKD population
- Still has sex limitation but more clinically focused

---

## FILES UPDATED/CREATED

### Files Updated:
1. ✅ `src/clinical/egfr.py` - Updated terminology and added sex impact analysis
2. ✅ `src/data/03_label_derivation_corrected.py` - New corrected script
3. ✅ `src/preprocessing/preprocessing.py` - Moved imputation into pipeline
4. ✅ `src/preprocessing/05_test_preprocessing.py` - Updated test script
5. ✅ `reports/label_derivation_corrected.md` - New corrected report
6. ✅ `reports/leakage_analysis_corrected.md` - New corrected report
7. ✅ `reports/corrected_methodology.md` - New comprehensive methodology report
8. ✅ `reports/methodology_audit.md` - Updated with correction status
9. ✅ `reports/FINAL_AUDIT_SUMMARY.md` - Updated with completion status

### New Files Created:
1. ✅ `data/processed/ckd_egfr_categories_observed_only.csv` - Dataset without imputed labels
2. ✅ `tests/validate_data_only.py` - Automated validation checks
3. ✅ `models/preprocessor_corrected.pkl` - Corrected preprocessor artifact

---

## AUDIT FINDINGS SUMMARY

### Target Definition: ✅ CORRECTED
- Previously: "CKD Stage 1-5" ❌
- Now: "eGFR-based severity category 1-5" ✅
- Clinical CKD requires evidence of kidney damage, not just eGFR

### eGFR Calculation: ⚠️ DOCUMENTED
- Using male-default equation without sex
- Overestimates eGFR for females by ~25%
- Sex distribution unknown, bias direction/magnitude unknown
- Now properly documented in all reports

### Label Generation: ✅ CORRECTED
- Previously: 26 samples (6.5%) with labels from imputed data ❌
- Now: 374 samples with labels from observed data only ✅
- No circular dependency

### Clinical Validity: ✅ CLARIFIED
- High eGFR does not equal no CKD (143 "notckd" in Categories 1-2)
- CKD diagnosis spans all eGFR categories
- Two targets measure different clinical constructs
- Now properly documented with disclaimers

### Preprocessing: ✅ CORRECTED
- Previously: Imputation before train/test split ❌
- Now: Imputation in pipeline (fit on train only) ✅
- Leakage-free preprocessing validated

### Target Leakage: ✅ CONTROLLED
- Three experimental configurations designed correctly
- Experiment B (no leakage) is primary focus
- Explicit documentation of leakage vs non-leakage experiments

### Class Distribution: ✅ ACCEPTABLE
- All classes have ≥10 samples (min: 52)
- Sufficient for stratified splitting
- Small dataset overall (374 samples)

---

## RECOMMENDATION

**PROCEED TO PHASE 4** with corrected methodology.

**Fix time completed:** 3 hours  
**Scientific validity:** Defensible as exploratory analysis  
**Clinical validity:** Limited (eGFR categories ≠ clinical CKD stages)

**Next step:** Proceed to Phase 4 (Feature Selection) using corrected methodology.

---

**Audit Completed:** 2026-09-14  
**Status:** AWAITING FIXES  
**Decision Point:** After fixes completed
